Literature DB >> 23929216

Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis.

G Caocci1, F Murgia2, L Podda3, A Solinas4, S Atzeni2, G La Nasa1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23929216     DOI： 10.1038/leu.2013.235

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  10 in total

1.  Ruxolitinib for myelofibrosis therapy: current context, pros and cons.

Authors:  A Pardanani
Journal:  Leukemia       Date:  2012-07       Impact factor: 11.528

Review 2.  Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy.

Authors:  Winnie Yeo; Philip J Johnson
Journal:  Hepatology       Date:  2006-02       Impact factor: 17.425

3.  A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.

Authors:  Srdan Verstovsek; Ruben A Mesa; Jason Gotlib; Richard S Levy; Vikas Gupta; John F DiPersio; John V Catalano; Michael Deininger; Carole Miller; Richard T Silver; Moshe Talpaz; Elliott F Winton; Jimmie H Harvey; Murat O Arcasoy; Elizabeth Hexner; Roger M Lyons; Ronald Paquette; Azra Raza; Kris Vaddi; Susan Erickson-Viitanen; Iphigenia L Koumenis; William Sun; Victor Sandor; Hagop M Kantarjian
Journal:  N Engl J Med       Date:  2012-03-01       Impact factor: 91.245

4.  Effect of interferon-γ and tumor necrosis factor-α on hepatitis B virus following lamivudine treatment.

Authors:  Hong Shi; Lu Lu; Ning-Ping Zhang; Shun-Cai Zhang; Xi-Zhong Shen
Journal:  World J Gastroenterol       Date:  2012-07-21       Impact factor: 5.742

5.  Tumor necrosis factor activates a conserved innate antiviral response to hepatitis B virus that destabilizes nucleocapsids and reduces nuclear viral DNA.

Authors:  Robyn Puro; Robert J Schneider
Journal:  J Virol       Date:  2007-05-02       Impact factor: 5.103

6.  Mutations and prognosis in primary myelofibrosis.

Authors:  A M Vannucchi; T L Lasho; P Guglielmelli; F Biamonte; A Pardanani; A Pereira; C Finke; J Score; N Gangat; C Mannarelli; R P Ketterling; G Rotunno; R A Knudson; M C Susini; R R Laborde; A Spolverini; A Pancrazzi; L Pieri; R Manfredini; E Tagliafico; R Zini; A Jones; K Zoi; A Reiter; A Duncombe; D Pietra; E Rumi; F Cervantes; G Barosi; M Cazzola; N C P Cross; A Tefferi
Journal:  Leukemia       Date:  2013-04-26       Impact factor: 11.528

7.  Efficacy of prophylactic lamivudine to prevent hepatitis B virus reactivation in B-cell lymphoma treated with rituximab-containing chemotherapy.

Authors:  Yin-Hua Wang; Lei Fan; Li Wang; Run Zhang; Ji Xu; Cheng Fang; Jian-Yong Li; Wei Xu
Journal:  Support Care Cancer       Date:  2012-11-15       Impact factor: 3.603

8.  The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection.

Authors:  Alessandro Zerbini; Massimo Pilli; Carolina Boni; Paola Fisicaro; Amalia Penna; Paola Di Vincenzo; Tiziana Giuberti; Alessandra Orlandini; Giuseppina Raffa; Teresa Pollicino; Giovanni Raimondo; Carlo Ferrari; Gabriele Missale
Journal:  Gastroenterology       Date:  2008-02-14       Impact factor: 22.682

9.  Reactivation of hepatitis viruses following immunomodulating systemic chemotherapy.

Authors:  Tsunamasa Watanabe; Yasuhito Tanaka
Journal:  Hepatol Res       Date:  2012-11-27       Impact factor: 4.288

10.  Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report.

Authors:  Claudia Colomba; Raffaella Rubino; Lucia Siracusa; Francesco Lalicata; Marcello Trizzino; Lucina Titone; Manlio Tolomeo
Journal:  BMC Res Notes       Date:  2012-10-05
  10 in total
  45 in total

1.  Specificity of JAK-kinase inhibition determines impact on human and murine T-cell function.

Authors:  F Perner; T M Schnöder; S Ranjan; D Wolleschak; C Ebert; M C Pils; S Frey; A Polanetzki; C Fahldieck; U Schönborn; B Schraven; B Isermann; T Fischer; F H Heidel
Journal:  Leukemia       Date:  2015-08-05       Impact factor: 11.528

Review 2.  Immunological Consequences of JAK Inhibition: Friend or Foe?

Authors:  Donal P McLornan; Alesia A Khan; Claire N Harrison
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

Review 3.  The Rationale for Immunotherapy in Myeloproliferative Neoplasms.

Authors:  Lucia Masarova; Prithviraj Bose; Srdan Verstovsek
Journal:  Curr Hematol Malig Rep       Date:  2019-08       Impact factor: 3.952

4.  Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib.

Authors:  M Massa; V Rosti; R Campanelli; G Fois; G Barosi
Journal:  Leukemia       Date:  2013-10-22       Impact factor: 11.528

Review 5.  Efficacy of ruxolitinib for myelofibrosis.

Authors:  Fabio P S Santos; Srdan Verstovsek
Journal:  Expert Opin Pharmacother       Date:  2014-05-24       Impact factor: 3.889

6.  Human Dendritic Cells Mitigate NK-Cell Dysfunction Mediated by Nonselective JAK1/2 Blockade.

Authors:  Shane A Curran; Justin A Shyer; Erin T St Angelo; Lillian R Talbot; Sneh Sharma; David J Chung; Glenn Heller; Katharine C Hsu; Brian C Betts; James W Young
Journal:  Cancer Immunol Res       Date:  2016-12-06       Impact factor: 11.151

Review 7.  JAK2 inhibitors for myeloproliferative neoplasms: what is next?

Authors:  Prithviraj Bose; Srdan Verstovsek
Journal:  Blood       Date:  2017-05-12       Impact factor: 22.113

8.  JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis.

Authors:  T Stübig; H Alchalby; M Ditschkowski; D Wolf; G Wulf; T Zabelina; C Wolschke; F Ayuk; N Kröger
Journal:  Leukemia       Date:  2014-02-26       Impact factor: 11.528

9.  Disseminated tuberculosis associated with ruxolitinib.

Authors:  R K Hopman; S J Lawrence; S T Oh
Journal:  Leukemia       Date:  2014-03-13       Impact factor: 11.528

Review 10.  Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy.

Authors:  Man Fai Law; Rita Ho; Carmen K M Cheung; Lydia H P Tam; Karen Ma; Kent C Y So; Bonaventure Ip; Jacqueline So; Jennifer Lai; Joyce Ng; Tommy H C Tam
Journal:  World J Gastroenterol       Date:  2016-07-28       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.